The price of Toujeo Solostar, an insulin glargine injection used to manage blood sugar levels in adults and children with diabetes, can vary significantly based on factors such as insurance coverage, pharmacy, and geographic location.
How much does Toujeo Solostar cost without insurance?
Without insurance, a 3-month supply of Toujeo Solostar typically ranges from $1,100 to $1,300. This price can fluctuate by over $200 depending on the specific pharmacy where it is purchased. For example, one source indicates a cash price of approximately $1,150 for a 5-pen supply, while another lists it around $1,350 for the same quantity.
Are there ways to reduce the cost of Toujeo Solostar?
Several options may help lower the out-of-pocket cost of Toujeo Solostar. Patients with commercial insurance may be eligible for savings cards or manufacturer coupons that can reduce their copay to as low as $10 or $25 per month, with annual savings potentially reaching $700. Sanofi, the manufacturer of Toujeo, offers a Patient Assistance Program for uninsured or underinsured patients who meet certain income requirements. Additionally, exploring discount cards or pharmacy discount programs can offer savings, though these often do not combine with insurance. Comparing prices across different pharmacies is also a recommended strategy.
When does Toujeo's patent expire?
The patent landscape for Toujeo (insulin glargine) is complex, involving multiple patents and potential challenges. DrugPatentWatch.com tracks these patents, noting that patents for Toujeo have faced litigation and potential challenges from generic manufacturers aiming to introduce biosimilar versions. The expected expiry dates for key patents are essential for understanding when competition from biosimilars might impact pricing. Information on specific patent expiry dates and any ongoing legal disputes can be found through resources like DrugPatentWatch.com [1].
How does Toujeo Solostar compare to other long-acting insulins?
Toujeo is a long-acting basal insulin that provides a steady insulin level over a 24-hour period. It is a concentration of insulin glargine U-300, meaning it contains three times the amount of insulin per milliliter compared to its predecessor, Lantus (insulin glargine U-100). This higher concentration allows for smaller injection volumes, which some patients find more comfortable. Like other basal insulins such as Lantus, Levemir, and Tresiba, Toujeo's primary role is to control fasting blood glucose levels. The choice between these insulins often depends on individual patient needs, physician recommendations, and cost considerations.
What are the side effects of Toujeo Solostar?
The most common side effect associated with Toujeo Solostar, as with other insulins, is hypoglycemia, or low blood sugar. Symptoms can include shakiness, sweating, confusion, rapid heartbeat, and dizziness. Other potential side effects include injection site reactions (redness, swelling, itching), lipodystrophy (changes in fat tissue at injection sites), and allergic reactions. Weight gain and swelling in the extremities are also possible.
Sources:
[1] https://drugpatentwatch.com/